Key statistics
As of last trade Stoke Therapeutics Inc (0GT:FRA) traded at 10.70, -33.54% below its 52-week high of 16.10, set on Jun 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.70 |
---|---|
High | 10.70 |
Low | 10.70 |
Bid | 10.90 |
Offer | 11.20 |
Previous close | 10.60 |
Average volume | 1.11 |
---|---|
Shares outstanding | 52.97m |
Free float | 50.59m |
P/E (TTM) | -- |
Market cap | 596.94m USD |
EPS (TTM) | -2.10 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:05 GMT.
More ▼
Press releases
- Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
- Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
- Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
- Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
- Stoke Therapeutics to Present at Upcoming Investor Conferences in September
More ▼